Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07826390 in Advanced Solid Tumors
NCT06546553Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Sep 2024
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-07826390 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), renal cell carcinoma (RCC) and 3 more, sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events at 90 days and 2 more. Started Sep 2024; status: terminated.
02
Drugs
PF-07826390
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)renal cell carcinoma (RCC)squamous cell carcinoma of the head and neck (HNSCC)ovarian cancer
Beyond the preview
Go deeper on NCT06546553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06546553.